At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Budesonide Spray Via Mucosal Atomization Device on the Hypothalamic-Pituitary Axis
In Brief
A Phase 2 clinical trial evaluating Mucosal Atomization Device (MAD) and Budesonide via Nasal Syringe for Chronic Rhinosinusitis. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Budesonide, a steroid subtype, has been used as an adjunctive treatment for chronic rhinosinusitis as a topical nasal steroid spray. The current standard of care at St. Paul's Sinus Centre is to administer budesonide via the Mucosal Atomization Device (MAD). It is believed that the MAD is a better device than the standard nasal lavage because its fine mist enhances absorption and improves bioavailability. No studies have been done to determine if enhanced absorption and improved bioavailability of budesonide via MAD could potentially affect the hypothalamic-pituitary-adrenal (HPA) axis, resulting in the suppression of our own body's production of natural steroids.
Study Details
Timeline
Interventions
The use of pulmicort via MAD once a day for a total of 30 days.
The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.